PMID- 20946321
OWN - NLM
STAT- MEDLINE
DCOM- 20120524
LR  - 20151119
IS  - 1755-5922 (Electronic)
IS  - 1755-5914 (Linking)
VI  - 30
IP  - 1
DP  - 2012 Feb
TI  - Unfractionated heparin during elective PCI: fixed dose or weight adjusted?
PG  - 1-4
LID - 10.1111/j.1755-5922.2010.00231.x [doi]
AB  - INTRODUCTION: To assess two different dosing strategies of unfractionated heparin 
      (UFH) during elective percutaneous coronary intervention (PCI). AIMS: The optimal 
      dose of heparin during elective PCI in patients with stable angina is unknown. 
      Existing guidelines are based on limited data. We interrogated data from the PCI 
      database. Patients with stable angina undergoing planned transradial PCI for 
      uncomplicated single lesions were included. The main endpoint was troponin I 
      release. We compared a fixed heparin dose (3000 U) UFH to a weight-adjusted dose. 
      RESULTS: Of 698 patients 244 (35.0%) received fixed dose (3000 U) and 454 (65.0%) 
      70 U/kg weight-adjusted UFH. There was no significant difference in median 
      troponin between the fixed dose and the weight-adjusted groups; 0.17 ng/mL versus 
      0.14; P= 0.21. The proportion of troponin positive patients was similar in both 
      groups (61.9% in the fixed dose group vs. 58.1%; P= 0.37). There were no deaths 
      or major ischemic events during hospitalization. There was no bleeding requiring 
      transfusion or delaying hospital discharge. CONCLUSION: In conclusion, this 
      retrospective observational study of elective transradial PCI demonstrated that a 
      reduced, fixed dose of periprocedural heparin was associated with similar 
      postprocedural troponin levels when compared to a standard weight-adjusted 
      regime. Our study further questions the optimal dose of heparin required during 
      elective PCI and suggests a need for further trials.
CI  - (c) 2010 Blackwell Publishing Ltd.
FAU - Kidambi, Ananth
AU  - Kidambi A
AD  - Department of Cardiology, Freeman Hospital and Institute of Cellular Medicine, 
      Newcastle University, Newcastle-upon-Tyne, UK.
FAU - Mayurathan, Gnanamoorthy
AU  - Mayurathan G
FAU - Viswanathan, Girish
AU  - Viswanathan G
FAU - Schechter, Clyde
AU  - Schechter C
FAU - Zaman, Azfar G
AU  - Zaman AG
LA  - eng
GR  - FS/033/07/British Heart Foundation/United Kingdom
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101014
PL  - England
TA  - Cardiovasc Ther
JT  - Cardiovascular therapeutics
JID - 101319630
RN  - 0 (Anticoagulants)
RN  - 0 (Biomarkers)
RN  - 0 (Troponin I)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Aged
MH  - Angina, Stable/etiology
MH  - *Angioplasty, Balloon, Coronary/adverse effects
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Biomarkers/blood
MH  - *Body Weight
MH  - Chi-Square Distribution
MH  - Coronary Artery Disease/complications/*therapy
MH  - *Drug Dosage Calculations
MH  - England
MH  - Female
MH  - Heparin/*administration & dosage/adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Radial Artery
MH  - Registries
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Troponin I/blood
EDAT- 2010/10/16 06:00
MHDA- 2012/05/25 06:00
CRDT- 2010/10/16 06:00
PHST- 2010/10/16 06:00 [entrez]
PHST- 2010/10/16 06:00 [pubmed]
PHST- 2012/05/25 06:00 [medline]
AID - 10.1111/j.1755-5922.2010.00231.x [doi]
PST - ppublish
SO  - Cardiovasc Ther. 2012 Feb;30(1):1-4. doi: 10.1111/j.1755-5922.2010.00231.x. Epub 
      2010 Oct 14.